Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Wenzhen Ge, Alexi Archambault, Thomas E. Delea, Karen Rodriguez Lorenc, James Harnett, Aaron Moynahan, Derek Weycker, Yariv Houvras, Glenn S. Kroog, Ning Wu, Christian Hampp, Qiufei Ma

Blood (2022) 140 (Supplement 1): 10897–10899.

https://doi.org/10.1182/blood-2022-158013

Published: 2022

Journal Articles

Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations

Nirmish Shah, Thokozeni Lipato, Thomas E. Delea, Alexander Lonshteyn, Derek Weycker, Andy Nguyen, Anne Beaubrun, Ofelia A. Alvarez

Blood (2022) 140 (Supplement 1): 1954–1956.

https://doi.org/10.1182/blood-2022-169536

Published: 2022

Journal Articles

Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States

Qiufei Ma, Xue Song, Thomas E. Delea, Glenn S. Kroog, Wenzhen Ge, Lei Chi, Aaron Moynahan, Derek Weycker, Karen Rodriguez Lorenc

Blood (2022) 140 (Supplement 1): 5298–5300.

https://doi.org/10.1182/blood-2022-158142

Published: 2022

Journal Articles

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Ahmar Urooj Zaidi, MD, Thokozeni Lipato, MD, Ofelia A. Alvarez, MD, Alexander Lonshteyn, PhD, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD, Nirmish Shah, MD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140525

Published: 2020

Journal Articles

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

William B Ershler, MD, Laura M De Castro, MD MHSc, Zahra Pakbaz, MD, Aaron Moynahan, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-140572

Published: 2020

Journal Articles

Healthcare Utilization (HRU) and Costs Among Multiple Myeloma (MM) Patients (Pts) Receiving Second or Subsequent Line Treatment (Tx) with Carfilzomib (CAR) or Pomalidomide (POM)

Sumeet Panjabi, PhD, May Hagiwara, PhD, Thomas E. Delea, MSIA

Blood (2016) 128 (22): 2419.

https://doi.org/10.1182/blood.V128.22.2419.2419

Published: 2016

Journal Articles

Patterns of Medication Use in Patients with Relapsed and/or Refractory Multiple Myeloma

May Hagiwara, PhD, Aaron Moynahan, MA, Ze Cong, Yaozhu J. Chen, MPA, Emilie Duchesneau, BA, Dana Hurley, PharmD, MS, Thomas E. Delea, MSIA

Blood (2015) 126 (23): 4497.

https://doi.org/10.1182/blood.V126.23.4497.4497

Published: 2015

Journal Articles

Cost-Effectiveness of Zoledronic Acid Versus Clodronate In Patients with Multiple Myeloma From a Canadian Healthcare System Perspective.

Thomas E. Delea, M.S.I.A., Khalid El Ougari, PhD, Jason Rotter, BA, Alice Wang, MA, Satyin Kaura, MEng, MBA, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 3812.

https://doi.org/10.1182/blood.V116.21.3812.3812

Published: 2010

Journal Articles

Retrospective, Nested, Case-Control Study of the Association between Transfusion Frequency and Potential Complications of Iron Overload in Patients with Myelodysplastic Syndrome and Other Acquired Hematopoietic Disorders.

Thomas E. Delea, May Hagiwara, Pradyumna D. Phatak

Blood (2006) 108 (11): 968.

https://doi.org/10.1182/blood.V108.11.968.968

Published: 2006

Journal Articles

Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.

Thomas E. Delea, MSIA, Oleg Sofrygin, MS, Jean-Francois Baladi, MBA, Simu K. Thomas, PhD, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 3134.

https://doi.org/10.1182/blood.V106.11.3134.3134

Published: 2005

Journal Articles

Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.

Thomas E. Delea, MSIA, May Hagiwara, PhD, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 5583.

https://doi.org/10.1182/blood.V106.11.5583.5583

Published: 2005

Journal Articles

Once-Daily Oral Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine as Iron Chelation Therapy in Patients with Sickle-Cell Disease Receiving Frequent Transfusions: A Cost-Effectiveness Analysis.

Thomas E. Delea, MSIA, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Thomas D. Coates, MD

Blood (2005) 106 (11): 5584.

https://doi.org/10.1182/blood.V106.11.5584.5584

Published: 2005

Journal Articles

Cost-Effectiveness Analysis of Oral Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Chelation Therapy with Deferoxamine in Patients with Transfusion-Dependent Myelodysplastic Syndrome.

Thomas E. Delea, MSIA, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD

Blood (2005) 106 (11): 5585.

https://doi.org/10.1182/blood.V106.11.5585.5585

Published: 2005

Journal Articles

Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.

Thomas E. Delea, MSIA, Oleg Sofrygin, MS, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 1341.

https://doi.org/10.1182/blood.V106.11.1341.1341

Published: 2005

NARROW

Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations

Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

Healthcare Utilization (HRU) and Costs Among Multiple Myeloma (MM) Patients (Pts) Receiving Second or Subsequent Line Treatment (Tx) with Carfilzomib (CAR) or Pomalidomide (POM)

Patterns of Medication Use in Patients with Relapsed and/or Refractory Multiple Myeloma

Cost-Effectiveness of Zoledronic Acid Versus Clodronate In Patients with Multiple Myeloma From a Canadian Healthcare System Perspective.

Retrospective, Nested, Case-Control Study of the Association between Transfusion Frequency and Potential Complications of Iron Overload in Patients with Myelodysplastic Syndrome and Other Acquired Hematopoietic Disorders.

Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.

Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.

Once-Daily Oral Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine as Iron Chelation Therapy in Patients with Sickle-Cell Disease Receiving Frequent Transfusions: A Cost-Effectiveness Analysis.

Cost-Effectiveness Analysis of Oral Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Chelation Therapy with Deferoxamine in Patients with Transfusion-Dependent Myelodysplastic Syndrome.

Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only